These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26129693)

  • 1. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today.
    Damas OM; Deshpande AR; Avalos DJ; Abreu MT
    J Crohns Colitis; 2015 Oct; 9(10):928-36. PubMed ID: 26129693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on pregnancy and breastfeeding in the era of biologics.
    Yarur A; Kane SV
    Dig Liver Dis; 2013 Oct; 45(10):787-94. PubMed ID: 23474350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis.
    Laube R; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2021 Mar; 20(3):275-292. PubMed ID: 33412078
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
    Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
    Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
    Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New advances in the treatment of inflammatory bowel disease].
    Chaparro M
    Gastroenterol Hepatol; 2013 Oct; 36 Suppl 2():21-9. PubMed ID: 24160949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.
    Papamichael K; Mantzaris GJ; Peyrin-Biroulet L
    Expert Opin Drug Saf; 2016; 15(4):493-501. PubMed ID: 26799429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of steroid-resistant inflammatory bowel disease.
    Manz M; Vavricka SR; Wanner R; Lakatos PL; Rogler G; Frei P; Safroneeva E; Schoepfer AM
    Digestion; 2012; 86 Suppl 1():11-5. PubMed ID: 23051721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
    Bousvaros A
    Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of inflammatory bowel disease in adults.
    Katz JA
    J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.